Table 1 Main oncogenic drivers and associated metabolic alterations in PLC
From: Metabolic reprogramming in the tumor microenvironment of liver cancer
Oncogenic drivers | Target molecules | Dysregulated metabolic pathways | PLC types (proportions) | References |
|---|---|---|---|---|
MYC OE | GLUT1/2 | Glycolysis | HCC (15%) | |
| Â | HK2 | Serine biosynthesis | iCCA (6%) | Â |
| Â | PKL/PKM | Â | Â | Â |
| Â | PSPH | Â | Â | Â |
TP53 mut | GLUT1/4 | Oxidative glycolysis | HCC (58%) | |
| Â | Â | Â | iCCA (21%) | Â |
CTNNB1 mut | PPARα | FAO | HCC (19%) | [65] |
| Â | GS | mTORC1 | Â | Â |
APOB mut | Â | VLDL secretion | HCC (10%) | [77] |
ALB mut | Â | Albumin production | HCC (9%) | [78] |
KRAS mut | GLUT1 | Glycolysis | iCCA (17%) | [90] |
IDH1/2 mut | αKG-dependent dioxygenases | TCA | iCCA (17%) | [92] |
BAP1 mut | Histone H2A and mitochondrial ubiquitination | Gluconeogenesis and lipid homeostasis | iCCA (12%) | [79] |